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Abstract Anandamide and allied fatty acylethanolamides (AEs)
may act as signalling molecules in brain and peripheral tissues. In
the present study, we describe an electron-impact gas chromato-
graphy/mass spectrometry (GC/MS) method based on isotope
dilution, which may be used for the identification and quantifica-
tion of anandamide and other AEs in biological matrices. The
calibration curves for standard AEs were linear over the range 0^
1000 pmol (r2 = 0.99) with a coefficient of variation of 4% at 2.5
pmol. Detection and quantification limits were in the high fmol to
low pmol range for all AEs. Using this method we measured
nanomolar concentrations of three endogenous AEs in depro-
teinated rat blood plasma (anandamide: 5.2 pmol/ml; palmit-
ylethanolamide: 16.7 pmol/ml; oleylethanolamide: 8.1 pmol/ml).
These results are consistent with a regulatory role of anandamide
and other AEs in peripheral tissues.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Anandamide (arachidonylethanolamide) is an endogenous
lipid that binds to cannabinoid receptors with high a⁄nity
[1] and mimics the pharmacological e¡ects of cannabimimetic
drugs both in vitro and in vivo [2]. Anandamide is released
from brain neurons in an activity-dependent manner [3]
through a mechanism that involves phospholipase D-mediated
cleavage of a membrane phospholipid precursor [4,5] ; carrier-
mediated uptake into cells followed by enzymatic hydrolysis is
thought to terminate its biological e¡ects [6^10]. Though ini-
tially isolated from brain, anandamide is widely distributed in
peripheral organs and tissues [11], where it may serve broad
regulatory functions including control of vascular tone [12^
14], intestinal motility [15,16] and immune responses [17].
Anandamide is structurally related to a family of saturated
and monounsaturated fatty acylethanolamides (AEs) which
have been long recognized as endogenous constituents of ani-
mal and plant tissues [18]. The possible physiological roles of
these compounds are still largely unexplored, but two lines of
evidence suggest that they may participate in cellular signal-
ling. First, saturated and monounsaturated AEs are produced,
together with anandamide, when cultured neurons are chal-
lenged with Ca2 ionophore or membrane-depolarizing agents
[3]. Second, AEs are pharmacologically active. For example,
palmitylethanolamide exerts signi¢cant antiin£ammatory ef-
fects when it is administered as a drug in various animal
models [19]. Some of these e¡ects may be mediated by the
activation of CB2-like cannabinoid receptors [20].
Reliable quantitative methods to measure anandamide and
other AEs at trace concentrations are needed to investigate
the possible regulatory functions of these compounds. In the
present study, we describe an isotope dilution, electron-impact
gas chromatography/mass spectrometry (GC/MS) method
which may have the sensitivity, selectivity, accuracy and pre-
cision required for this analytical task. We applied this assay
to the quanti¢cation of anandamide and other AEs in rat
blood plasma.
2. Materials and methods
2.1. Chemicals
Bis(trimethylsilyl)tri£uoroacetamide (BSTFA) was from Supelco
(Bellefonte, PA), [3H]anandamide (221 Ci/mmol) from New England
Nuclear (Wilmington, DE), fatty acyl chlorides (5,8,11,14-eicosate-
traenoylchloride, hexadecanoylchloride and 9-octadecenoylchloride)
from Nu-Check Prep (Elysian, MN), [2H4]ethanolamine (isotopic
atom enrichment = 98%) from Cambridge Isotope Laboratories (And-
over, MA). All solvents were from Burdick and Jackson (Muskegon,
MI) and all other chemicals from Sigma (St. Louis, MO).
2.2. Synthesis of standard AEs and [2H4]AEs
Standard AEs were synthesized by the reaction of fatty acyl chlo-
rides with unlabeled or 2H4-labeled ethanolamine [1]. Fatty acyl chlo-
rides in dichloromethane (10 mg/ml) were mixed with 1 equivalent of
ethanolamine, and allowed to react for 15 min at 0^4‡C. Reactions
were stopped by adding water. After vigorous mixing, the upper aque-
ous phases were discarded to remove unreacted ethanolamine. The
organic phases were washed twice with water, concentrated to dryness
under a stream of N2, and the reaction products were reconstituted in
methanol. Identity and chemical purity (s 98%) of the synthesized
AEs and [2H4]AEs were determined by GC/MS (see Section 2.4).
2.3. Extraction and fractionation of rat plasma AEs
5 ml of blood was collected from the heart of anesthetized male
Wistar rats using a syringe ¢lled with 2 ml Krebs-Tris bu¡er (NaCl
136 mM, KCl 5 mM, MgCl2 1.2 mM, CaCl2 2.5 mM, glucose 10 mM,
Trizma base 20 mM; pH 7.4) containing EDTA 4.5 mM. Blood
samples were centrifuged in Accuspin tubes (Sigma) for 10 min at
18‡C (800Ug) and the plasma layers were carefully recovered and
spiked with [2H4]AEs (600 pmol each). After acetone precipitation
of plasma proteins, the supernatants were collected and subjected to
lipid extraction with methanol/chloroform. Enough of each solvent
was added to reach a ¢nal ratio bu¡er/methanol/chloroform of
1:1:2 (v/v/v). The chloroform phases were recovered, evaporated to
dryness under N2, reconstituted in chloroform (50 Wl) and injected
into the HPLC. HPLC fractionations were performed on a Hewlett-
Packard 1090 Liquid Chromatograph, equipped with a normal-phase
Resolve Silica column (3.9 mmU15 cm, 5 Wm, Waters Associates),
eluted with a gradient of isopropyl alcohol (B) in n-hexane (A) (100%
A initial; 90% A, 10% B for 1 min; 60% A, 40% B for 7 min, 50% A,
50% B for 12 min) at a £ow rate of 1.7 ml/min. Under these con-
ditions, all AEs were eluted from the HPLC column between 4.7 and
5.3 min. The AE-containing fractions were collected in glass reaction
vessels (Supelco), dried under N2 and subjected to chemical derivati-
zation (see Section 2.4). To estimate recoveries, in some experiments
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[3H]anandamide (20 000 dpm) was added to an aqueous solution (1
ml) of non-radioactive anandamide (100 nM), extracted in chloro-
form/methanol and subjected to HPLC fractionation. The AE-con-
taining fractions were concentrated to a volume of 1 ml under N2,
and radioactivity was determined by liquid scintillation counting.
2.4. GC/MS analysis
The AEs were derivatized by treatment with BSTFA for 15 min at
room temperature. The trimethylsilylether (TMS) derivatives pro-
duced in this reaction were dried under N2, reconstituted in n-hexane
and injected in the splitless mode into a Hewlett-Packard 5890 GC
equipped with an HP-5MS capillary column (30 m; internal diameter,
0.25 mm) and interfaced with a Hewlett-Packard 5972 MS. Starting
one minute after the injection, the oven temperature was increased
from 150‡C to 280‡C at a rate of 8‡C/min. The injector temperature
was kept at 250‡C and helium was used as carrier gas. The ion energy
was 25 eV and the accelerating voltage was 1.6 V. Under these con-
ditions, the TMS derivatives of [2H4]AE standards were eluted from
the GC at the following retention times: [2H4]anandamide: 18.6 min;
[2H4]palmitylethanolamide: 15.6 min; [2H4]oleylethanolamide: 17.3
min. Because of GC isotope discrimination, unlabeled AEs had reten-
tion times approximately 0.02 min longer than the corresponding
[2H4]AEs. We monitored, by selected-ion monitoring (SIM), AE frag-
ments produced by the loss of one methyl group ([M-15]).
3. Results and discussion
3.1. Mass spectral properties of AEs and [2H4]AEs
The electron-impact mass spectra of synthetic unlabeled
anandamide (cis20:4), palmitylethanolamide (16:0) and ole-
ylethanolamide (cis18:1) are shown in Fig. 1. Diagnostic frag-
ments for all compounds were found in the high mass range.
They included molecular ions ([M]) as well as ions produced
by the loss of one methyl group ([M-15]). Additional inform-
ative and prominent fragments were: [M-43] (loss of one
propyl group); [M-90] (loss of TMSOH group; this fragment
was absent from the spectrum of anandamide-TMS which
contained instead a fragment at m/z 328, [M-91]) ; and m/z
175/179 (possibly corresponding to [H2CNCOH^NH^CH2^
CH2^O^TMS], which may be produced through McLa¡erty
rearrangement).
3.2. Linearity of the isotope dilution assay
Monitoring the [M-15] fragments, which are reasonably
abundant in the AE-TMS spectra, we observed MS responses
that were linear (r2 = 0.99) when amounts of unlabeled AEs
ranging from 0 to 1000 pmol were injected into the GC/MS
together with a ¢xed amount of 2H4-labeled standards (600
pmol).
3.3. Precision and accuracy
Precision and accuracy of the method were assessed in ¢ve
independent determinations by injecting 2.5, 10 or 100 pmol
of each AE together with 600 pmol of the corresponding
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Fig. 1. Electron impact mass spectra of the TMS derivatives of anandamide (A), palmitylethanolamide (B), and oleylethanolamide (C).
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standard. The estimates obtained in these analyses are re-
ported in Table 1. Percent coe⁄cients of variation (CV)
were calculated dividing the standard deviation by the sample
mean and multiplying the resulting value by 100.
3.4. Limit of detection (LOD) and limit of quanti¢cation
(LOQ)
When monitoring the [M-15] fragments of 2H4-labeled AE
standards by SIM, we obtained the following labeled/unla-
beled ratios: 0.012 for anandamide, 0.0009 for palmityletha-
nolamide and 0.0087 for oleylethanolamide. These blank val-
ues were plotted in calibration curves as corresponding to 0
pmol. The LOD, i.e. the injected quantity which produced a
signal corresponding to an average blank plus 3 standard
deviations, was 0.4 pmol for anandamide, 0.1 pmol for pal-
mitylethanolamide, and 0.1 pmol for oleylethanolamide.
The LOQ, i.e. the lowest quantity which could be measured
with acceptable accuracy (arbitrarily set at a CV6 20%), was
determined by injecting into the GC/MS varying amounts of
AEs together with 600 pmol of the corresponding 2H4-labeled
standards. The lowest quanti¢able mass was 2 pmol for anan-
damide (CV = 4%; n = 5), 1.25 pmol for oleylethanolamide
(CV = 8.5%; n = 3), and 0.6 pmol for palmitylethanolamide
(CV = 9.6%; n = 3).
3.5. Identi¢cation and quanti¢cation of AEs in rat blood
plasma
Synthetic [2H4]AEs (600 pmol each) were added to plasma
samples, proteins were precipitated with acetone, and lipids in
the supernatant were extracted with chloroform/methanol.
Preliminary tests indicated that the acetone precipitation
step was necessary to assure the elimination of contaminating
components present in plasma and to obtain a satisfactory
chromatographic fractionation. The lipid extracts were sub-
jected to normal-phase HPLC using a method previously pub-
lished by our laboratory [21], but modi¢ed to require a shorter
elution time (see Section 2). Under these conditions, all AEs
were eluted together from the column at a retention time
comprised between 4.7 and 5.3 min. Considering the time
necessary to re-equilibrate the column, the fractionation of
one sample was completed in approximately 20 min. Although
time-consuming, this HPLC step was essential, as it signi¢-
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Table 1
Precision and accuracy of the method
Injected amount (pmol) Measured amount (pmol þ S.D.) Precision (CV, %) Accuracy
Actual/nominal (%) Actual3nominal (pmol)
Anandamide
2.5 2.5 þ 0.1 4 100 0
10 9.8 þ 0.1 1 98 30.2
100 100.8 þ 1.4 1.4 100.8 0.8
Palmitylethanolamide
2.5 2.5 þ 0.1 4 100 0
10 10.2 þ 0.2 1 103 0.3
100 100.1 þ 3,0 3 100.1 0.1
Oleylethanolamide
2.5 2.5 þ 0.1 4 100 0
10 10.3 þ 0.1 1 103 0.3
100 100.0 þ 1.6 1.6 100 0
Fig. 2. Representative selected ion recording of a rat blood plasma sample showing the presence of components with the chromatographic
properties of anandamide. Anandamide was partially puri¢ed by normal-phase HPLC and analyzed by GC/MS in the SIM mode as TMS de-
rivative. The arrow indicates the retention time of authentic standard. Results are from one experiment, representative of six.
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cantly improved GC resolution and prolonged GC column
life. The overall recovery of the extraction and fractionation
procedures, measured in six independent experiments by using
[3H]anandamide as a tracer, was 68.0 þ 2.5%.
In plasma samples from six rats, we observed components
which were eluted from the GC at the retention times ex-
pected for anandamide, palmitylethanolamide and oleyletha-
nolamide (Fig. 2 and data not shown). These components
coeluted with the corresponding 2H4-labeled AE standards,
and displayed the following diagnostic fragments: anand-
amide, m/z 419, [M] and m/z 404, [M-15] ; palmitylethanol-
amide, m/z 356, [M-15] ; oleylethanolamide, m/z 382, [M-15]
(Fig. 2 and data not shown). These results indicate that de-
proteinated rat plasma contains detectable levels of the three
endogenous AEs. A quantitative estimate of AE plasma con-
centrations, obtained in 12 independent determinations from
six rats, revealed 5.2 þ 1 pmol/ml of anandamide, 16.7 þ 2.7
pmol/ml of palmitylethanolamide and 8.1 þ 1.2 pmol/ml of
oleylethanolamide.
4. Conclusions
Quantitative measurements of anandamide and other AEs
in biological samples are hindered by the low concentrations
of these compounds in tissues and by their high adsorption to
glass and plastic surfaces. The isotope dilution GC/MS meth-
od described in the present study should help overcome such
di⁄culties. This method, in combination with other recently
published ones [22^24], may be applied in future studies aimed
at determining the changes in AE content occurring in blood
plasma, cerebrospinal £uid or brain microdialysis perfusates
under various physiological and pathological conditions, or
during drug administrations. Here, we have used it to deter-
mine AE levels in rat blood plasma. Our results show that low
nanomolar concentrations of AEs may be readily measured in
plasma samples which had been deproteinated by acetone
treatment. This result is at variance with a previous study in
which anandamide could not be detected in human plasma by
using a HPLC/MS/MS method [11]. Possible explanations for
this discrepancy include di¡erences in sample preparation (e.g.
deproteination), extraction or fractionation. The concentra-
tion of anandamide in plasma reported here is well below
those considered su⁄cient to activate cannabinoid receptors
of either the CB1 or CB2 subtype [1,25], particularly when
taking into account that anandamide may be extensively
bound to serum proteins. Therefore, our results do not sup-
port a role of anandamide as a circulating hormone. However,
in light of the low concentrations of anandamide in brain
[4,5,11] and of its short half-life in vivo (5^15 min) [26], the
results do suggest that peripheral tissues represent a signi¢cant
source of circulating anandamide. In keeping with this possi-
bility, anandamide formation was recently described in stimu-
lated macrophages [24], and was suggested to participate in
the life-threatening hypotension that accompanies hemor-
rhagic shock [27].
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